In this week’s issue:
- W. Garfield Weston Foundation – Transformational Request for Proposals on Neurodegenerative Diseases of Aging (reminder)
- Canada Research Chairs Internal Faculty of Medicine Competition (reminder)
- Western Diversification Program – Invitation to Apply
- The Centre for Blood Research Seminar Series – “Platelet Targeted Gene Therapy for Hemophilia”
LOI Deadline: March 25, 2013 (by 8:00am PST)
The W. Garfield Weston Foundation is seeking proposals for high potential, translational research or clinical trials that will have transformational impact in neurodegenerative diseases of aging.
To be eligible, projects must fall into one of these two categories to be considered:
– Preclinical to Phase III development of a therapeutic
– Development of tools that help accelerate the development of therapeutics e.g., animal models, imaging techniques or reagents, biomarkers or diagnostics
The Foundation defines translational and therapeutic as follows:
– Translational: Applied research towards developing therapeutics for the prevention and/or treatment of human disease (e.g., for small molecule drug development, target validation to early Phase II clinical trials).
– Therapeutic: Drugs (including small molecules, biologics, cell therapies and vaccines), medical devices or surgical interventions regulated by regulatory bodies such as the FDA. This definition includes therapeutics for all stages of disease including symptomatic relief, prevention, diagnosis and disease modification, but does not include complementary approaches such as exercise or acupuncture.
The basis for funding will be impact on neurodegenerative diseases of aging; however, research may be in any disease. Of diseases that affect more than 1,000 Canadians, the Foundation considers the following to be neurodegenerative diseases of aging:
– Alzheimer’s disease
– Parkinson’s disease
– Dementia with Lewy Bodies
– Frontotemporal dementia
– Amyotrophic lateral sclerosis
– Multiple system atrophy
– Mild cognitive impairment as prodromal to one of the above diseases
The Foundation will commit up to $4 million to this funding program. Grants can be up to $500,000 per project each year over three years to a maximum of $1.5 million per project.
Deadline: March 28, 2013
The Faculty of Medicine is launching an internal Canada Research Chairs (CRC) competition to fill three vacant CRC Tier 2 Chairs who will go forward to the national CRC competition in October 2013.
These Chairs will be available for: a) Tier 2 Retention, b) Tier 2 New Recruitment, or c) Tier 2 to Tier 1 advancement.
Please find the full details for the competition at the website above.
I am pleased to inform you of Western Economic Diversification Canada’s (WD) new application process for the Western Diversification Program (WDP)
WDP is targeting non-profit organizations and industry associations undertaking initiatives that will strategically position Western Canada to grow, innovate, compete, and create jobs. Projects will be considered that align with WD’s current priorities of trade and investment, business productivity and growth, and technology commercialization.
Please take time to review this information about WDP and how to apply for funding on the following website: http://www.wd.gc.ca/eng/301.asp. If you know of an organization that would benefit from this information, please feel free to pass it along. For specific questions call 1-888-338-WEST (9378) or e-mail email@example.com.
The Centre for Blood Research Seminar Series – “Platelet Targeted Gene Therapy for Hemophilia”
Date: March 5th, 2013
Location: LSC 3 – Life Sciences Centre, 2350 Health Sciences Mall
Presented by Dr. Bob Montgomery
Senior Investigator, Blood Research Institute/BloodCentre of Wisconsin
Professor, Department of Pediatrics, Medical College of Wisconsin
*Please note the special date and time of this seminar*